Best Life Sciences Companies in Milan, Italy
The 58 best Life Sciences companies in Milan, Italy in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AAVantgarde Bio.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Milan
| # | Company | Last round | Disclosed funding | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Aequilibrium pharma Provider of proteins and protein services | — | — | 1 | 2018 | — | — | — |
| 2 | Airon Telematica Web-based clinical data capture and data management solutions | — | — | — | 2000 | Andrea De Rosa Founder & CEO | — | — |
| 3 | amplifon Amplifon is a global leader in the hearing care retail market, empowers people to rediscover all the emotions… | — | — | 13,195 | 1950 | — | — | — |
| 4 | Axxam Provider of services for research application across life sciences industries | — | — | 186 | 2001 | Stefan Lohmer Chief Executive Officer | 23 patents Enhanced bioluminescent photoproteins for intracellular calcium imaging and assay reagents | — |
| 5 | BIOREK Developer of the screening, diagnosis, and prognosis solutions for renal cell carcinoma | — | — | 3 | 2019 | — | 2 patents Renal cell carcinoma diagnostic biomarkers | — |
| 6 | Bios Medical lasers and aesthetic devices for dermatology | — | — | — | 1982 | Aldo Casalino CEO | 52 patents Non‑invasive RF and EMS technologies for body contouring, cellulite reduction, and skin remodeling | — |
| 7 | Bioscience Institute Provides stem cell banking services | — | — | — | 2004 | Giuseppe Mucci Founder & CEO | 6 patents CAR-T cell therapies targeting B‑cell receptors for immunotherapy | — |
| 8 | Bone System A portfolio of dental products | — | — | — | 1991 | Vetzy Perez Palma CEO | — | — |
Top 12 Life Sciences companies in Milan
#1
Public · Milan, Lombardy · founded 2014 · 9 employees$33.6Mraised▾
Developer of lentivirus-based gene and cell therapies for cancer. The lead candidateTemferon is a lentivirus-based hematopoietic stem progenitor cell immuno-gene therapy for Glioblastoma, solid tumor, and hematological malignancies. Also, has Tie2-Expressing Monocytes immunotherapies for multiple cancer treatment.
- Mar 2025Post IPO$21.9M
- Sep 2019Series C$14.6M
- Sep 2017Series B$8M
- Mar 2015Series A$11M
#2
Series A · Milan, Lombardy · founded 2004 · 32 employees$15.8Mraised▾
Provider of automated solutions for in liquid biopsy. It offer a pre‑analytical workstation for blood samples at the collection siteand separates plasma and stabilizes cellular fraction directly on nanocoated SmartBioSurface microscope slides ideal for detecting circulating tumor cells (CTCs) and preserving cell-free plasma.
- Jan 2025PE$15.3M
- Aug 2018Grant (prize money)$58.4K
- May 2018Grant (prize money)$60K
- Jun 2016Grant (prize money)$340.2K
#3
Series A · Milan, Lombardy · founded 2021 · 4 employees$65.3Mraised▾
Developer of gene therapies for inherited retinal disorders. The company is developing Adeno-Associated Viral (AAV) vectors for the delivery of large genes to the tissue and cells targeting genetic blindness.
- Jun 2023Series A$65.3M
- Jun 2021Seed—
#4
Series C · Milan, Lombardy · founded 2011 · 40 employees$29.6Mraised▾
WISE is a provider of solutions for neuromodulation and neuromonitoring. It has developed minimally invasive, biocompatible, foldable, and stretchable implantable leads for neuromodulation and neuromonitoring. The foldable nature of their electrodes and wires enables them to be implanted into the area of interest such as spine through a minimally invasive surgery. It provides a flexible electrode that can be folded and introduced into the spinal column using a catheter, thereby allowing it to be used to treat back pain and others. It also provides solutions for mapping of brain activity and pre-surgical epilepsy monitoring. Wise produces their electrodes through a proprietary process called supersonic cluster beam implantation (SCBI) technology, whereby nanoparticles of platinum and iridium are embedded into a silicon-based substrate, creating a composite layer below the surface that becomes an electro-conductive skin.
- Aug 2022Grant (prize money)$50.1K
- Oct 2020Series C$17.6M
- Aug 2019Grant (prize money)$55.1K
- May 2017Series B$7.3M
#5
Public · Milan, Lombardy · founded 1999 · 23 employees$54.9Mraised▾
Therapies for patients with diseases of the central nervous system and pain. It has a pipeline of drug candidates which include Xadago (safinamide) for the treatment of Parkinson’s disease, Evenamide (NW-3509) for the treatment of patients with positive symptoms of schizophrenia, Sarizotan for patients with Rett syndrome, and ralfinamide for patients with specific rare pain indications.
#6
Seed · Milan, Milan · founded 2019 · 3 employees$1.9Mraised▾
Developer of therapeutics for neurological disorders. It provides calcilytics-based medications or negative allosteric modulators that can block CaSR activation and slow the progression of Alzheimer's disease.
- May 2023Seed$1.9M
#7
Acquired · Milan, Lombardy · founded 2007 · 25 employees$31.7Mraised▾
Developer of an erythrocyte encapsulation drug delivery system. The company has developed the proprietary red cell loader (RCL) non-invasive device and erykit that helps in loading on human red blood cells with small molecules such as protein and enzymes. The company has multiple therapeutics in the pipeline such as erdex is in the 3rd stage of clinical trials and eetm has completed the 2nd phase of the clinical trial.
- Apr 2018Series B$31.7M
- Jan 2016Grant (prize money)$4.7M
- Jul 2013Series B—
- Series A—
#8
Series A · Milan, Lombardy · founded 2011 · 5 employees$3.9Mraised▾
Provider of a minimally invasive device for the treatment of varicose veins. The company offers treatment of varicose veins using its propriety technology - sclerotherapy technique catheter and three balloons for sclerotherapy. The catheter is inserted, the vein is isolated and blood is replaced, then the drug is released and absorbed for recovery.
- May 2022Series A$1.8M
- 2021Seed$1.2M
- 2021Seed$849.5K
#9
Seed · Milan, Lombardy · founded 2022$2.5Mraised▾
Developer of therapeutics for cancer treatment. It offers anticancer therapies that are focused on the regulation of the activation of T lymphocytes to a sequence of human DNA to kill cancer cells.
- Sep 2022Seed$2.5M
#10
Series A · Milan, Lombardy · founded 2017 · 5 employees$19.3Mraised▾
Developer of stem cell-based therapeutics for cancer and autoimmune diseases. The drugs provide the expression of programmed death-ligand 1 (PD-L1) at molecular and protein levels by lentiviral vector-based engineering of patients’ hematopoietic stem cells used for the treatment of type 1 diabetes and multiple sclerosis. The company's lead product candidates used against these two diseases are in pre-clinical trials.
- Sep 2018Series A$19.3M
#11
Seed · Milan, Lombardy · founded 2017 · 9 employees$697.1Kraised▾
Provider of organs-on-chip platforms for preclinical studies. The company is pioneering the generation of predictive models of human organs and pathologies to test compound toxicity/functionality in a high-throughput fashion. The company organs portfolio comprises uBeat, a human heart-on-chip, and uKnee, a model of the human osteoarthritic joint.
- Oct 2022Seed$200K
- Jun 2022Grant (prize money)$79.8K
- Feb 2020Grant (prize money)$55K
- Dec 2019Grant (prize money)$55.1K
#12
Seed · Milan, Lombardy · founded 2021 · 7 employees$534.6Kraised▾
Provider of DNA test kits for personalized health recommendations. The company offers home-based saliva test kits for genetic analysis, based on test results users can receive personalized recommendations for nutritional paths, physical activity, and well-being.
- Feb 2023Seed$534.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Milan is moving
A read on the academic research around Biotechnology in Milan — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 84 papers.
Milan's University of Milan and Milano-Bicocca lead moderately optimistic biotechnology research (stance 0.32) focused primarily on DNA repair, plant stress tolerance, and livestock genetics.
- University of Milan77
- University of Milano-Bicocca7
- Consorzio Milano Ricerche1
- DNA damage3
- Mutant2
- Phosphorylation2
- Genome1
- Viral replication1
- Abiotic stress4
- Human health4
- Arabidopsis3
- Gene knockdown3
- Gene silencing3
- Genetic diversity2
- Dairy cattle2
- Production (economics)2
- Antibiotic resistance2
- Antibiotics2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.